NCT01841125

Escitalopram for the Treatment of Depression in Alzheimer's Disease

A 12-Week Randomized, Double-blind, Parallel-group, Placebo-controlled Trial With and Open-label, 12-week Extension, Multicenter to Evaluation of the Efficacy of Escitalopram for the Treatment of Depression in Alzheimer's Disease

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 84 (actual)
• Sponsor: Konkuk University Medical Center · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

Purpose : to Evaluation of the Efficacy of Escitalopram for the Treatment of Depression in Alzheimer's Disease Trial Design : A 12-week, randomized, double-blind, parallel-group, placebo-controlled trial with an open-label, 12-week extension

Detailed description

Clinical trial agreement signed by the parties to the subjects through a process of screening. if it is consider suitable for evaluating through the selection / exclusion criteria, they will be randomly assigned to the test group or control group (placebo). Assigned to the test group or control subjects, they will be prescribe the 5mg Escitalopram or Placebo. without regard to meals, it will be taking once a day. and than It should be increased the capacity every two weeks by 5mg/day up to a maximum 15mg/day. and than, on the treatment for a 8 weeks, If you don't find the side effect, Maintaining the same capacity. If you find the side effect, you should lose capacity.(10mg/day) The test group or control subjects, will receive a doctor's examination and inspection through six visits for a 24weeks from the date of the randomly assigned participants.

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	escitalopram	escitalopram 15mg, QD(once a day), Oral medication, 24weeks
DRUG	Placebo	placebo 15mg, QD(once a day), Oral medication

Timeline

• Start date: 2011-11-01
• Primary completion: 2014-07-01
• Completion: 2014-07-01
• First posted: 2013-04-26
• Last updated: 2014-08-13

Locations

1 site across 1 country: South Korea